Polatuzumab vedotin obinutuzumab venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

Rajat Bannerji,Sam Yuen,Tycel J. Phillips,Christopher Arthur,Iris Isufi,Paula Marlton,John F. Seymour,Paolo Corradini,A. Molinari,Giuseppe Gritti,Robert Emmons,Jamie Hirata,Lisa Musick,Sourish Saha,Brandon Croft,Christopher R. Flowers

Polatuzumab vedotin obinutuzumab venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

2021

Rajat Bannerji
Sam Yuen
Tycel J. Phillips
Christopher Arthur
Iris Isufi
Paula Marlton
John F. Seymour
Paolo Corradini
A. Molinari
Giuseppe Gritti
Robert Emmons
Jamie Hirata
Lisa Musick
Sourish Saha
Brandon Croft
Christopher R. Flowers

7534Background: Polatuzumab vedotin (Pola) + obinutuzumab (G) demonstrated activity and tolerability in a Phase 1b/2 trial of patients (pts) with R/R FL (Phillips, et al. Blood 2016). Preclinical s...

Keywords:

in patient
Tolerability
Obinutuzumab
Medicine
Internal medicine
Follicular lymphoma
Oncology
Polatuzumab vedotin
relapsed refractory
Venetoclax

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations